Palisade Bio annual operating margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2023
Palisade Bio's operating margin was −5,228.00% for fiscal 2023.
View full Palisade Bio company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −5,228.00% | +63536.79 pp |
| 2020 | 2020-12-31 | −68,764.79% | −12692.99 pp |
| 2019 | 2019-12-31 | −56,071.81% | −52895.09 pp |
| 2018 | 2018-12-31 | −3,176.71% | +1941.40 pp |
| 2017 | 2017-12-31 | −5,118.12% | +121909.11 pp |
| 2016 | 2016-12-31 | −127,027.23% | +56869.56 pp |
| 2015 | 2015-12-31 | −183,896.78% | −91315.42 pp |
| 2014 | 2014-12-31 | −92,581.37% | −81195.97 pp |
| 2013 | 2013-12-31 | −11,385.40% | −8894.29 pp |
| 2012 | 2012-12-31 | −2,491.11% | +834.45 pp |
| 2011 | 2011-12-31 | −3,325.56% | −1255.19 pp |
| 2010 | 2010-12-31 | −2,070.37% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −2,339.60% | +71300.40 pp |
| Q1 2023 | 2023-03-31 | −1,011.60% | +32052.59 pp |
| Q4 2020 | 2020-12-31 | −145,981.44% | −60678.52 pp |
| Q3 2020 | 2020-09-30 | −72,640.00% | +12327.00 pp |
| Q2 2020 | 2020-06-30 | −73,640.00% | −49338.24 pp |
| Q1 2020 | 2020-03-31 | −33,064.19% | +65198.41 pp |
| Q4 2019 | 2019-12-31 | −85,302.92% | −13110.32 pp |
| Q3 2019 | 2019-09-30 | −84,967.00% | −1660.04 pp |
| Q2 2019 | 2019-06-30 | −24,301.76% | −23500.58 pp |
| Q1 2019 | 2019-03-31 | −98,262.60% | −4302.80 pp |
| Q4 2018 | 2018-12-31 | −72,192.60% | −71293.99 pp |
| Q3 2018 | 2018-09-30 | −83,306.96% | +20207.96 pp |
| Q2 2018 | 2018-06-30 | −801.18% | +167928.06 pp |
| Q1 2018 | 2018-03-31 | −93,959.80% | +75320.48 pp |
| Q4 2017 | 2017-12-31 | −898.61% | +63724.72 pp |
| Q3 2017 | 2017-09-30 | −103,514.92% | +93165.28 pp |
| Q2 2017 | 2017-06-30 | −168,729.24% | −15358.48 pp |
| Q1 2017 | 2017-03-31 | −169,280.28% | +80064.20 pp |
| Q4 2016 | 2016-12-31 | −64,623.34% | +109428.90 pp |
| Q3 2016 | 2016-09-30 | −196,680.20% | +11220.60 pp |
| Q2 2016 | 2016-06-30 | −153,370.76% | +46418.12 pp |
| Q1 2016 | 2016-03-31 | −249,344.48% | −91203.24 pp |
| Q4 2015 | 2015-12-31 | −174,052.24% | −74588.78 pp |
| Q3 2015 | 2015-09-30 | −207,900.80% | −125765.90 pp |
| Q2 2015 | 2015-06-30 | −199,788.88% | −129564.12 pp |
| Q1 2015 | 2015-03-31 | −158,141.24% | −33905.56 pp |
| Q4 2014 | 2014-12-31 | −99,463.46% | +11039.46 pp |
| Q3 2014 | 2014-09-30 | −82,134.90% | +63224.54 pp |
| Q2 2014 | 2014-06-30 | −70,224.76% | +59199.32 pp |
| Q1 2014 | 2014-03-31 | −124,235.69% | −121414.44 pp |
| Q4 2013 | 2013-12-31 | −110,502.92% | −1429.88 pp |
| Q3 2013 | 2013-09-30 | −145,359.44% | −143847.34 pp |
| Q2 2013 | 2013-06-30 | −129,424.08% | −126373.51 pp |
| Q1 2013 | 2013-03-31 | −2,821.25% | −1244.79 pp |
| Q4 2012 | 2012-12-31 | −109,073.04% | −105956.47 pp |
| Q3 2012 | 2012-09-30 | −1,512.10% | — |
| Q2 2012 | 2012-06-30 | −3,050.57% | — |
| Q1 2012 | 2012-03-31 | −1,576.46% | — |
| Q3 2011 | 2011-09-30 | −3,116.57% | — |
Over the last five reported fiscal years, Palisade Bio's operating margin increased from −127,027.23% to −5,228.00%, a change of +121799.23 percentage points. The latest reported quarter, Q2 2026, shows −2,339.60%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Palisade Bio filings at SEC.gov ↗